Clinical trial of GDNF

This pioneering trial tested whether GDNF treatment can slow, stop or reverse Parkinson's - something no current treatment can do.

GDNF is a special protein that is naturally produced inside the brain and supports the survival of many types of brain cells – including the cells lost in Parkinson's.

GDNF trial results offer hope for Parkinson's

The results from the GDNF clinical trial are not clearcut, but offer promising signs that it may be possible to restore the cells damaged in Parkinson's.

Read the latest news about the GDNF clinical trial.

What's next for GDNF?

We're excited about the future of GDNF as a treatment for Parkinson's. And we’re fully committed to exploring the potential it could hold.

Now we need more research to take GDNF forwards. 

We're working with the scientific team, companies, charities and patients to explore possible routes to further studies.


Slice title
GDNF trial results in detail

Slice text

The trial has advanced our understanding of the potential effects of GDNF on damaged brain cells. It has proved that delivering a therapy in this way is feasible and acceptable to patients. And it has shown that it's possible to deliver drugs with precision to the brain.

In this short animation we look at the trial results and what they mean for Parkinson's.